Cancer Trials Ireland is pleased to announce the launch of a new report on The Value of Cancer Clinical Trials on Monday, 10 November 2025, at 10:30 a.m.
This report will highlight some of the estimated treatment-cost savings and inward investment generated by cancer clinical trials in Ireland, thereby emphasising their value to patients, the Exchequer, and Ireland Inc. The report calls for increased government support for cancer clinical trials and for Cancer Trials Ireland, through the Health Research Board (HRB), with the current HRB grant cycle concluding in 2026.
Speakers:
- Angela Clayton-Lea, CEO of Cancer Trials Ireland
- Dr Anne Fortune, Consultant Haematologist, Mater Hospital
- Seamus Cotter, Patient Consultants Committee, Cancer Trials Ireland
- Prof Seamus O’Reilly, Clinical Lead, Cancer Trials Ireland
- Prof Sinead Brennan, SLRON & Irish Research Radiation Oncology Group (IRROG)
- Amy Nolan, Director of Clinical Services, Irish Cancer Society
Alongside economic impacts, the CTI report will review Ireland’s overall performance in clinical trials (all trials & oncology trials) vs. Europe, and track improvements identified on study start-up timelines.
Cancer Trials Ireland anticipates this report will complement and support the upcoming publication of the National Clinical Trials Oversight Group’s (NCTOG) findings and recommendations.
While we are facilitating virtual and in-person attendance at this launch, due to very limited in-person capacity, registration via the button below (Eventbrite) is for virtual attendance only at this time. If you would like to attend in person, please email comms@cancertrials.ie and we will provide details about the in-person event (RCSI, Dublin 2) if capacity allows.
Links to join the online meeting will be emailed to all registrants ahead of November 10th.